1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65C26EA0B00B51B2D002587B5003AFE4B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/5C26EA0B00B51B2D002587B5003AFE4B?OpenDocument
18
19OpenDocument
2054.161.98.96
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB






Products & Services >> Best Practice Database >>Archived Research Alerts >>November 2021 Research

NOVEMBER 2021 Research Alert

This month we added five new studies to the Best Practice Database, the research repository for Best Practices, LLC. This month's new studies explore several topical areas, including how a diagnostic tool can support a rare disease product launch; how to manage hostile stakeholders during launch; and how pharma is utilizing social media for HCP education and IME grants for patient education. The first study examines how the launch of Vyndamax/Vyndaqel was aided by an associated diagnostic tool. The next two studies regarding hostile stakeholders examine how organizations are relying on strategies built on winning over patients and working with KOLs/Payers/Activists. The final two studies look at current trends around the use of social media for medical education and the utilization of IME grants for patient education and medical sponsorships

The new Best Practices, LLC studies listed below under Newly Added Research explore how leading companies have made their operations more effective across these different areas.


Download: Accelerating Launch Success through Improved Diagnosis of Rare Diseases: How Vyndamax/Vyndaqel Created a Blockbuster through Faster, Easier and More Frequent Diagnosis of ATTR-CM (5702)

Best Practices, LLC produced this case study to uncover the winning strategies and tactics used by Pfizer to create a blockbuster launch for Vyndamax/Vyndaqel through faster and improved diagnosis of rare disease, ATTR-CM.


Download: Managing Hostile Stakeholders during the Launch of a Breakthrough New Medicine: Winning Patients to Your Side (5703)

This study engaged senior launch leadership from pharma companies and utilized extensive secondary research to probe key aspects including: turning citizens into political influencers; working with patient advocacy groups; and winning patients to your side.


Download: Managing Hostile Stakeholders during the Launch of a Breakthrough New Medicine: Working with KOLs, Payers, and Activist Groups (5704)

Best Practices, LLC engaged senior launch leadership from pharma companies and conducted extensive secondary research to probe key aspects including: working with KOLs and HCPs; working with activist groups; and working with payer groups.


Download: How Pharma is Utilizing Social Media for Delivering Medical Education (5705)

This study highlights current trends and future directions for pharma utilizing social platforms for HCP education, in particular public and closed social media platforms. The study also presents the traits of effective public and closed social media platforms and hurdles to social media utilization.


Download: How Pharma is Utilizing IME Grants for Patient Education and Medical Sponsorships (5706)

Best Practices, LLC conducted this study to highlight current trends and future directions for how pharma is utilizing IME programs for medical patient education activities, sponsorships, and corporate memberships.